Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation.

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Abstract Text:

T Yoshida,S Yamagishi,T Matsui,K Nakamura,T Ueno,M Takeuchi,M Sata,

This study examined whether telmisartan, a unique angiotensin II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, improved insulin resistance in advanced glycation end-product (AGE)-exposed human hepatoma (Hep3B) cells. AGE increased phosphorylation of insulin receptor substrate-1 (IRS-1) at serine-307 residues in Hep3B cells. It also decreased tyrosine phosphorylation of IRS-1 and, subsequently, reduced the association of the p85 subunit of phosphatidylinositol 3-kinase with IRS-1 and glycogen synthesis in insulin-exposed Hep3B cells, all of which were inhibited by telmisartan. The insulin-sensitizing properties of telmisartan in AGE-exposed Hep3B cells were significantly blocked by GW9662, an inhibitor of PPAR-gamma. Candesartan, another ARB, did not affect AGEs-induced serine phosphorylation of IRS-1 at serine-307 residues in Hep3B cells. Our study suggests that telmisartan could improve AGE-elicited insulin resistance in Hep3B cells by inhibiting serine phosphorylation of IRS-1, at least in part, via activation of PPAR-gamma. Telmisartan may play a protective role against hepatic insulin resistance in diabetes.

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Publishing Authors By Initials

T Yoshida,S Yamagishi,T Matsui,K Nakamura,T Ueno,M Takeuchi,M Sata,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of international medical research

VOLUME: 36

Page Numbers: 237-43

Journal Abbreviation: J. Int. Med. Res.

ISSN: 0300-0605

DAY: 2

MONTH: 04

YEAR: 2008

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 346411

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation.

AFFILIATION: Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Int Med Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product AGE-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation Related Publications

• A human T-cell lymphotropic virus type-1 (HTLV-1) carrier complicated with various autoimmune diseases including primary biliary cirrhosis.
• Accumulation of mono-glycosylated form-rich, plaque-forming PrPSc in the second atypical bovine spongiform encephalopathy case in Japan.
• Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance.
• Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins.
• Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases.
• Chlamydia trachomatis proctitis.
• Confocal laser microscopy of chondrocytes that received gene transfer using in vitro electroporation.
• Considerations for general anesthesia combined with epidural anesthesia in a patient with stiff-person syndrome.
• Epidemiological survey of oral lichen planus among HCV-infected inhabitants in a town in Hiroshima Prefecture in Japan from 2000 to 2003.
• Granulocytapheresis (GCAP) for severe alcoholic hepatitis-A preliminary report.
• Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
• HBV and HCV infection in Japanese dental care workers.
• Insulin resistance and lichen planus in patients with HCV-infectious liver diseases.
• Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
• Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis.
• Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
• Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.
• Open sesame! CXCR4 blockade recruits neutrophils into the plaque.
• Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells.
• Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes.
• Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
• Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients.
• Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection.
• Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation.
• The Effects of Ethanol on beta2-Integrin and l-Selectin on the Surface of Leukocytes in Human Whole Blood.
• The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function.
• Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
• Timing of interferon therapy and sources of infection in patients with acute hepatitis C.
• [A periappendiceal abscess during combination interferon and ribavirin treatment for chronic hepatitis C]
• [Incidence of insertion difficulty using Proseal LMA and the efficacy of recommended insertion maneuvers]